A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage i to IIIA non-small-cell lung cancers

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1272-1277

  Drilon, Alexander ^a   Sugita, Hirofumi ^b   Sima, Camelia S ^a   Zauderer, Marjorie ^a   Rudin, Charles M ^a   Kris, Mark G ^a   Rusch, Valerie W ^a   Azzoli, Christopher G ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Epigenetics; Non small cell lung cancer; Promoter methylation; Resected; Tumor suppressor gene

Indexed keywords

ADAMTS8 PROTEIN; APC PROTEIN; CDH13 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DAPK1 PROTEIN; GLUTATHIONE TRANSFERASE P1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WIF1 PROTEIN; DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; DNA METHYLATION; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; SMOKING; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84906228998     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000256     Document Type: Article

References (29)

1. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286-298.
2. Shenker NS, Polidoro S, van Veldhoven K, et al. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet 2013;22:843-851.
3. Vendetti FP, Rudin CM. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther 2013;13:1273-1285.
4. Wen J, Fu J, Zhang W, Guo M. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod Pathol 2011;24:932-943.
5. Buckingham L, Penfield Faber L, Kim A, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 2010;126:1630-1639.
6. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-1128.
7. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-271.
8. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
9. Shinjo K, Kondo Y. Clinical implications of epigenetic alterations in human thoracic malignancies: epigenetic alterations in lung cancer. Methods Mol Biol 2012;863:221-239.
10. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-3418.
11. Brabender J, Usadel H, Metzger R, et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected nonsmall cell lung cancer: associations with clinical outcome. Clin Cancer Res 2003;9:223-227.
12. Lehmann U, Länger F, Feist H, Glöckner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-612.
13. Hoffmann AC, Kaifi JT, Vallböhmer D, et al. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J Surg Oncol 2009;100:414-417.
14. Heller G, Venkatraman ES. A nonparametric test to compare survival distributions with covariate adjustment. J R Stat Soc 2004;66:719-733.
15. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
16. Helman E, Naxerova K, Kohane IS. DNA hypermethylation in lung cancer is targeted at differentiation-associated genes. Oncogene 2012;31:1181-1188.
17. Castro M, Grau L, Puerta P, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 2010;8:86.
18. Morán A, Fernández-Marcelo T, Carro J, et al. Methylation profiling in non-small cell lung cancer: clinical implications. Int J Oncol 2012;40:739-746.
19. Lu C, Soria JC, Tang X, et al. Prognostic factors in resected stage I nonsmall- cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004;22:4575-4583.
20. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-525.
21. Fox JL. Master Protocol for squamous cell lung cancer readies for launch. Nat Biotechnol 2014;32:116-118.
22. Underhill-Day N, Hill V, Latif F. N-terminal RASSF family: RASSF7- RASSF10. Epigenetics 2011;6:284-292.
23. Wang J, Lee JJ, Wang L, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable nonsmall cell lung cancer. Clin Cancer Res 2004;10(18 Pt 1):6119-6125.
24. Choi N, Son DS, Song I, et al. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Int J Cancer 2005;115:575-581.
25. Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:2362-2368.
26. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-4720.
27. Yang TM, Leu SW, Li JM, et al. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. J Cancer Res Clin Oncol 2009;135:919-924.
28. Arai T, Yasuda Y, Takaya T, et al. Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer. Cancer Detect Prev 2000;24:252-257.
29. Grimminger PP, Maus MK, Schneider PM, et al. Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC. Lung Cancer 2012;78:87-91.